GO:0036026 protein C inhibitor-PLAT complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036026 describes a heterodimeric protein complex formed by protein C inhibitor (SERPINA5) and tissue-type plasminogen activator (PLAT).
• Formation of the SERPINA5-PLAT complex inhibits the serine protease activity of tissue-type plasminogen activator, thereby regulating fibrinolysis.
• The complex is part of the broader protein C pathway, which controls coagulation, inflammation, and cell survival.
• SERPINA5 is a multifunctional serpin that also inhibits activated protein C (APC) and other proteases, linking the complex to vascular disease.
• Elevated levels of APC-protein C inhibitor complexes have been reported in peripheral arterial disease and aortic aneurysms.
• Research on this complex employs knockout, point-mutation, and knock-in cell models to dissect its role in thrombosis and vascular biology.
Description
The protein C inhibitor-PLAT complex (GO:0036026) is a heterodimeric assembly of protein C inhibitor (SERPINA5) and tissue-type plasminogen activator (PLAT). This complex is a key molecular entity in the regulation of serine protease activity within the blood coagulation and fibrinolytic systems. Protein C inhibitor is a member of the serpin superfamily, and its interaction with PLAT results in the inhibition of PLAT's enzymatic activity, thereby modulating clot dissolution. Understanding this complex is essential for researchers studying hemostasis, thrombosis, and vascular disease, as it represents a point of crosstalk between procoagulant and anticoagulant pathways. The complex has been detected in plasma and is considered a marker of activated coagulation and fibrinolysis. Its study offers insights into the pathogenesis of arterial and venous thrombotic disorders.
protein C inhibitor-PLAT complex At A Glance
| GO ID | GO:0036026 |
|---|---|
| GO term | protein C inhibitor-PLAT complex |
| Ontology | cellular_component |
| Synonym | PCI-PLAT complex; plasma serine protease inhibitor-PLAT complex; protein C inhibitor-tissue-type plasminogen activator complex; protein C inhibitor-tPA complex; serpin A5-PLAT complex; SERPINA5-PLAT complex |
| Major function | Inhibition of tissue-type plasminogen activator (PLAT) serine protease activity |
| Complex members | SERPINA5 (protein C inhibitor) and PLAT (tissue-type plasminogen activator) |
| Biological context | Regulation of fibrinolysis and coagulation |
| Related pathway | Protein C pathway |
What Is GO:0036026?
GO:0036026 is a cellular component term describing a heterodimeric protein complex that contains protein C inhibitor (SERPINA5) and tissue-type plasminogen activator (PLAT). Formation of this complex inhibits the serine protease activity of tissue-type plasminogen activator.
Why Is protein C inhibitor-PLAT complex Important in Cell Biology?
The protein C inhibitor-PLAT complex is important because it directly modulates the activity of tissue-type plasminogen activator, a key enzyme in the fibrinolytic system. By inhibiting PLAT, the complex helps regulate the balance between clot formation and dissolution, a process critical for preventing thrombosis or excessive bleeding. Dysregulation of this complex has been associated with vascular diseases such as peripheral arterial disease and aortic aneurysms. Moreover, protein C inhibitor is a multifunctional serpin that interacts with several proteases, positioning the complex at the intersection of coagulation, inflammation, and tissue remodeling. Research into this complex can inform the development of diagnostics and therapeutics for thrombotic disorders.
• Regulates fibrinolysis by inhibiting tissue-type plasminogen activator (PLAT).
• Serves as a biomarker for activated coagulation and fibrinolysis in vascular disease.
• Links the protein C anticoagulant pathway to the fibrinolytic system.
• Protein C inhibitor (SERPINA5) also inhibits activated protein C, affecting thrombin generation.
• Complex formation may influence inflammation and tissue repair.
• Relevant to peripheral arterial disease and aortic aneurysm pathogenesis.
• Provides a target for studying serpin-protease interactions.
• Potential therapeutic target for modulating clot stability.
• Used as a model to understand serpin conformational changes and inhibitory mechanisms.
• Helps explain inter-individual variability in thrombotic risk.
Structure and Composition of protein C inhibitor-PLAT complex
Protein C Inhibitor (SERPINA5)
In simple terms: SERPINA5 is the 'brake' that stops PLAT from working.
Protein C inhibitor, encoded by SERPINA5, is a 57-kDa serine protease inhibitor (serpin) synthesized primarily in the liver and secreted into plasma. It contains a reactive center loop that acts as a bait for target proteases, including activated protein C and tissue-type plasminogen activator. The serpin fold allows it to undergo a conformational change upon cleavage, trapping the protease in a stable complex.
Tissue-Type Plasminogen Activator (PLAT)
In simple terms: PLAT is the 'clot buster' that activates plasminogen to dissolve clots.
PLAT, also known as tPA, is a serine protease that catalyzes the conversion of plasminogen to plasmin, leading to fibrin degradation. It consists of several domains, including a catalytic serine protease domain and kringle domains that mediate fibrin binding. PLAT activity is tightly regulated by inhibitors such as SERPINA5.
Heterodimer Assembly
In simple terms: SERPINA5 and PLAT stick together to form a two-part complex.
The complex forms when the reactive center loop of SERPINA5 interacts with the active site of PLAT, resulting in a covalent acyl-enzyme intermediate that subsequently stabilizes into a tight heterodimer. This interaction is stoichiometric and irreversible, effectively removing PLAT from the circulation. The complex can be detected in plasma using specific antibodies or activity assays.
Structural Features of the Complex
In simple terms: The shape of the complex locks PLAT in an inactive state.
Upon complex formation, SERPINA5 undergoes a major conformational change, inserting its reactive center loop into its own beta-sheet A and translocating PLAT to the opposite pole of the serpin. This distortion disrupts the catalytic triad of PLAT, rendering it inactive. The complex is stable and can be recognized by conformation-specific antibodies.
Related Complexes and Multifunctionality
In simple terms: SERPINA5 can also pair with other proteases, not just PLAT.
SERPINA5 also forms complexes with activated protein C (APC), thrombin, and other proteases, contributing to its multifunctional role in hemostasis. The APC-protein C inhibitor complex is a marker of coagulation activation and has been studied in vascular diseases. The PLAT complex represents one of several inhibitory interactions mediated by SERPINA5.
Key Genes Involved in GO:0036026 protein C inhibitor-PLAT complex
The following genes and proteins are central to the biology of the protein C inhibitor-PLAT complex.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SERPINA5 | Encodes protein C inhibitor, the serpin component of the complex | Target for knockout and point-mutation studies to assess inhibitory function |
| PLAT | Encodes tissue-type plasminogen activator, the protease inhibited by SERPINA5 | Knockout and overexpression models to study fibrinolysis |
| PROC | Encodes protein C, a zymogen activated to APC, which is also inhibited by SERPINA5 | Point mutations linked to thrombosis |
| PROCR | Encodes endothelial protein C receptor, which enhances APC generation | Knock-in models to study protein C pathway |
| THBD | Encodes thrombomodulin, a cofactor for protein C activation | Relevant to coagulation regulation |
| F2 | Encodes prothrombin, the precursor of thrombin, which is inhibited by SERPINA5 | Knockout models to study thrombin generation |
| F5 | Encodes factor V, a cofactor in coagulation | Point mutations (e.g., Factor V Leiden) affect thrombosis risk |
| F8 | Encodes factor VIII, a cofactor in coagulation | Relevant to hemophilia and thrombosis models |
| F9 | Encodes factor IX, a serine protease in coagulation | Knockout models for hemophilia B |
| F10 | Encodes factor X, a serine protease in coagulation | Target for anticoagulant studies |
| F11 | Encodes factor XI, a serine protease in coagulation | Knockout models for thrombosis |
| F12 | Encodes factor XII, a serine protease in contact activation | Knockout models for thrombosis and inflammation |
| SERPINC1 | Encodes antithrombin, a major anticoagulant serpin | Knockout models for thrombosis |
| SERPINE1 | Encodes plasminogen activator inhibitor-1, which also inhibits PLAT | Overexpression models for fibrinolysis |
| PLG | Encodes plasminogen, the substrate of PLAT | Knockout models for fibrinolysis |
| PLAU | Encodes urokinase-type plasminogen activator, another PLAT-like protease | Comparative studies with PLAT |
| PLAUR | Encodes the urokinase receptor, involved in cell surface proteolysis | Knockout models for cancer and inflammation |
How Is protein C inhibitor-PLAT complex Regulated?
The formation and activity of the protein C inhibitor-PLAT complex are regulated at multiple levels. SERPINA5 expression is modulated by inflammatory cytokines and hormones, while PLAT activity is controlled by its own inhibitors (e.g., SERPINE1) and by fibrin binding. The protein C pathway, which includes APC and its cofactors, influences the availability of SERPINA5 for PLAT inhibition. Additionally, genetic variations in PROC and other components can alter the balance of complex formation, as seen in thrombotic disorders. The complex itself is a marker of activated coagulation and fibrinolysis, reflecting the interplay between these systems.
protein C inhibitor-PLAT complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SERPINA5 | Thrombosis, vascular disease | Knockout mice or cell lines to assess PLAT inhibition |
| PLAT | Fibrinolysis, thrombosis | Overexpression and knockout models to study clot lysis |
| PROC | Thrombophilia | Point-mutation knock-in models (e.g., Met343Val) |
| PROCR | Vascular inflammation | Knock-in reporter models to track expression |
| THBD | Atypical hemolytic uremic syndrome | Knockout models to study complement-coagulation crosstalk |
Thrombotic and Vascular Diseases
Elevated levels of APC-protein C inhibitor complexes have been observed in patients with peripheral arterial disease and aortic aneurysms, suggesting that complex formation is a marker of vascular pathology. The protein C pathway, which includes SERPINA5, is critical for maintaining hemostatic balance, and its dysfunction can lead to thrombosis. Mutations in PROC, such as Met343Val, can disrupt activated protein C function and cause thrombosis, potentially affecting the interaction with SERPINA5.
Coagulation Disorders
The protein C inhibitor-PLAT complex is part of the broader coagulation cascade. Deficiencies or abnormalities in protein C, protein S, or antithrombin can shift the balance toward thrombosis. SERPINA5 also inhibits thrombin and activated protein C, and its multifunctional nature means that alterations in its levels or activity can contribute to bleeding or clotting disorders. Understanding the complex's role may aid in diagnosing and managing such conditions.
Inflammation and Tissue Remodeling
Protein C inhibitor is expressed in various tissues and has been implicated in inflammation and wound healing. The PLAT complex may influence these processes by modulating plasmin generation and extracellular matrix turnover. Further research is needed to fully elucidate the role of the complex in inflammatory diseases.
From protein C inhibitor-PLAT complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SERPINA5 inhibit PLAT in vivo? | SERPINA5 knockout mouse or cell line |
| How does the Met343Val mutation affect APC function? | Point-mutation knock-in cell model |
| Can we visualize the SERPINA5-PLAT complex in real time? | Tagged knock-in of SERPINA5 or PLAT with fluorescent protein |
| What is the effect of PLAT overexpression on fibrinolysis? | PLAT overexpression cell line or transgenic mouse |
| Which genes interact with the complex? | CRISPR library screening in relevant cell types |
| How does the complex affect coagulation gene expression? | RNA-seq after knockout or overexpression |
How to Study the protein C inhibitor-PLAT complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Concentration of SERPINA5-PLAT complex | Biomarker studies in plasma |
| Western blot | Presence of covalent complex | In vitro inhibition assays |
| PLAT activity assay | Plasminogen activation | Functional validation of inhibition |
| CRISPR knockout | Loss of gene function | Studying complex role in cells |
| Point mutation knock-in | Effect of specific variants | Modeling thrombotic mutations |
| Fluorescence microscopy | Subcellular localization | Visualizing complex assembly |
| RNA-seq | Transcriptional changes | Pathway analysis after perturbation |
| Bioinformatics | Interaction networks | Identifying novel partners |
Proteomic and Biochemical Assays
The SERPINA5-PLAT complex can be detected and quantified using enzyme-linked immunosorbent assays (ELISA) with antibodies specific to the complex or to each component. Western blotting under non-reducing conditions can reveal the covalent complex. Activity assays measuring PLAT-mediated plasminogen activation in the presence of SERPINA5 provide functional validation.
Genetic and CRISPR Approaches
CRISPR-Cas9 knockout of SERPINA5 or PLAT in cell lines (e.g., HepG2, HeLa) allows assessment of complex formation and downstream effects on fibrinolysis. Point mutations can be introduced to mimic naturally occurring variants, such as those in PROC, to study their impact on complex stability. Knock-in of tagged versions enables imaging and interaction studies.
Imaging and Structural Biology
Fluorescence microscopy of tagged proteins can visualize co-localization and complex assembly in live cells. Structural studies using X-ray crystallography or cryo-EM have elucidated the serpin-protease complex architecture, revealing the conformational changes that inactivate PLAT.
Transcriptomic and Bioinformatics Analyses
RNA-seq after genetic perturbation can identify genes whose expression changes in response to complex disruption. Bioinformatics tools can predict interactions and pathways involving SERPINA5 and PLAT, integrating data from public databases.
How CRISPR Can Be Used to Study GO:0036026 protein C inhibitor-PLAT complex
Knockout
CRISPR-Cas9 knockout of SERPINA5 or PLAT can abolish complex formation, leading to altered fibrinolysis and coagulation phenotypes. Such models are useful for determining the physiological relevance of the complex in thrombosis and hemostasis.
Point Mutation
Introducing point mutations (e.g., in the reactive center loop of SERPINA5 or the active site of PLAT) can dissect the molecular determinants of complex formation and stability. This approach mimics naturally occurring variants and helps link genotype to function.
Knock-in
Knock-in of tagged or reporter versions of SERPINA5 or PLAT allows real-time tracking of complex assembly and localization. This is valuable for imaging studies and for isolating the complex for biochemical analysis.
Overexpression
Overexpression of SERPINA5 or PLAT in cell lines can drive complex formation and reveal downstream effects on gene expression and cellular behavior. This is particularly useful for studying the impact of elevated inhibitor levels in disease states.
How EDITGENE Supports protein C inhibitor-PLAT complex Research
Researchers studying protein C inhibitor-PLAT complex-related genes often need to determine whether a candidate gene is causally involved in complex assembly, regulation, or downstream effects. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for protein C inhibitor-PLAT complex research.
Frequently Asked Questions About protein C inhibitor-PLAT complex
What is the protein C inhibitor-PLAT complex?
It is a heterodimeric protein complex of SERPINA5 and PLAT that inhibits the serine protease activity of tissue-type plasminogen activator.
What genes are involved in the protein C inhibitor-PLAT complex?
The complex is formed by SERPINA5 (protein C inhibitor) and PLAT (tissue-type plasminogen activator).
What is the function of GO:0036026?
GO:0036026 describes a cellular component that inhibits PLAT activity, thereby regulating fibrinolysis.
How is the protein C inhibitor-PLAT complex regulated?
Its formation is regulated by the availability of SERPINA5 and PLAT, which are influenced by inflammatory cytokines, hormones, and other protease inhibitors.
What diseases are associated with the protein C inhibitor-PLAT complex?
Elevated levels of related complexes have been found in peripheral arterial disease and aortic aneurysms, and the complex is linked to thrombotic disorders.
What methods are used to study the protein C inhibitor-PLAT complex?
ELISA, Western blot, activity assays, CRISPR knockout, point mutation, and imaging are commonly used.
Can CRISPR be used to study the protein C inhibitor-PLAT complex?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the complex's function.
What is the role of SERPINA5 in the complex?
SERPINA5 acts as the inhibitory serpin that binds and inactivates PLAT.
What is the role of PLAT in the complex?
PLAT is the target protease whose activity is inhibited upon complex formation.
How does the protein C inhibitor-PLAT complex affect coagulation?
By inhibiting PLAT, the complex reduces plasmin generation and fibrin degradation, thus modulating clot stability.
Conclusion
The protein C inhibitor-PLAT complex (GO:0036026) is a critical molecular entity at the interface of coagulation and fibrinolysis. Its formation leads to the inhibition of tissue-type plasminogen activator, thereby regulating clot dissolution and vascular homeostasis. Dysregulation of this complex has been implicated in thrombotic and vascular diseases, making it a subject of intense research. Advances in CRISPR-based gene editing and high-throughput screening now allow precise dissection of the complex's components and their roles in health and disease. Continued investigation promises to uncover new therapeutic strategies for thrombosis and related disorders.
References
- 1. Kubier A et al.. 2012. Endogenous anticoagulants.. Top Companion Anim Med 27(2):81-7 PMID: 23031460
- 2. Blomstrand D et al.. 2010. Activated protein C-protein C inhibitor complex in peripheral arterial disease.. Ann Vasc Surg 24(5):588-95 PMID: 20409682
- 3. Norris LA. 2003. Blood coagulation.. Best Pract Res Clin Obstet Gynaecol 17(3):369-83 PMID: 12787532
- 4. Esmon CT. 2003. The protein C pathway.. Chest 124(3 Suppl):26S-32S PMID: 12970121
- 5. Stojanovski BM et al.. 2020. Zymogen and activated protein C have similar structural architecture.. J Biol Chem 295(45):15236-15244 PMID: 32855236
- 6. Zhou S et al.. 2024. Met343Val mutation disrupts the shuttling of Trp380 leading to a low-activity conformer of activated protein C and causes thrombosis.. J Thromb Haemost 22(8):2270-2280 PMID: 38788977
- 7. Kölbel T et al.. 2006. Activated protein C-protein C inhibitor complex: a new biological marker for aortic aneurysms.. J Vasc Surg 43(5):935-9 PMID: 16678686
- 8. Espana F et al.. 2005. The multifunctional protein C system.. Curr Med Chem Cardiovasc Hematol Agents 3(2):119-31 PMID: 15853699
